Observations placeholder
Tocilizumab or atlizumab trade names Actemra and RoActemra
Identifier
017738
Type of Spiritual Experience
Background
A description of the experience
Tocilizumab (or atlizumab, sold under the trade names Actemra and RoActemra) is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R).
On Jan, 06, 2017 11,911 people reported to have side effects when taking Actemra.
Among them, 17 people (0.14%) have Hallucination
Time on Actemra when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 33.33% | 66.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |